Notably, FTY20-Mitoxy, a derivate of the sphingosine-1-phosphate receptor modulator fingolimod clinically approved for multiple sclerosis (MS), reduced insoluble α-syn accumulation and prevented motor impairments in a transgenic MSA mouse model overexpressing α-syn under a 2′-3′-cyclic nucleotide 3′-phosphodiesterase (CNP) promoter (CNP-hα-syn mice). This evidence concerns the gene CNP and myeloid sarcoma.